Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging 2014 Meeting

Josh Mailman, President of the NorCal CarciNET Community  and Chair of the Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day on June 8th during the SNMMI 2014 Annual Meeting, to be held June 7-11 in St. Louis, Missouri.Society of Nuclear Medicine and Molecular Imaging 2014 Annual Meeting

SNMMI has long been committed to supporting patients, partnering with patient advocacy organizations on issues of mutual interest and priority, and providing educational programs to help patients understand molecular imaging and its role in both diagnostic and therapeutic settings. For the fourth year, the SNMMI Patient Advocacy Advisory Board has developed a “Patient Program” to address key topics of interest to the patient and patient advocacy community. The 2014 patient program provides a unique opportunity to network with passionate advocates and leading experts in neuroendocrine tumors (NETs), colorectal cancer, prostate cancer, and thyroid cancer.

Josh Mailman, Chair, Patient Advocacy Advisory Board, Society of Nuclear Medicine and Molecular Imaging

Josh Mailman

According to Mr. Mailman, “The SNMMI Patient Advocacy Advisory Board is dedicated to educating patients about nuclear medicine and molecular imaging so that they can make the best healthcare decisions for their individual needs.“

The program for the day includes presentations on “How Can Nuclear Medicine and Molecular Imaging Help You” and “Safety of Nuclear Medicine: What Do You Want to Know About Radiation and Nuclear Medicine;” a patient lunch with technologists, a panel of patients and their physicians talking about their partnerships and how patient involvement and empowerment has improved their care management; and breakout sessions on the latest advances for NETs, colorectal, prostate and thyroid cancer. A guided tour of the exhibit hall will give participants a first-hand look at the science and technology behind nuclear medicine and molecular imaging and therapy and the opportunity to meet representatives from key pharmaceutical and equipment manufacturing companies.

In the area of neuroendocrine tumors, the breakout session “Think Zebra: The Future of Imaging and Therapy for Neuroendocrine Tumors” will feature the following:

  • Introduction and Welcome from NorCal CarciNET Community                                           Josh Mailman
  • Understanding Diagnostic and Treatment Options for Neuroendocrine Tumors, Where Nuclear Imaging and Molecular Imaging Fit In                                                                          Eric H. Liu, MD
Dr. Eric H. Liu, Director of the Vanderbilt Neuroendocrine Center

Dr. Eric H. Liu

  • Theranostics – New Perspectives on Personalized Care for NETs                                       Richard P. Baum, MD, PhD
Prof Dr med Richard P. Baum, Bad Berka, Germany

Dr. Richard P. Baum

The SNMMI meeting schedule will also include presentations by national and  international carcinoid/NET physicians. During the June 7th Theranostics Nuclear Medicine in Oncology – Updates and Future Directions session, Dr. Richard Baum will speak on “Updates in Peptide Receptor Radionuclide Therapy” and Dr. Richard J. Campeau, Clinical Professor of Radiology (Nuclear Medicine) and Internal Medicine (Cardiology) at LSU and Tulane University Health Sciences Centers, will speak on “Radionuclide Therapy in Neuroendocrine Tumors.”

Dr. Richard J. Campeau to speak on Radionuclide Therapy for Neuroendocrine Tumors at Society of Nuclear Medicine and Molecular Imaging 2014 Meeting

Dr. Richard J. Campeau

For further information about the SNMMI Patient Education Day and to register, click here.

Print Friendly, PDF & Email